Avian CD154 enhances humoral and cellular immune responses induced by an adenovirus vector-based vaccine in chickens

Comparative Immunology, Microbiology and Infectious Diseases

Volumn 34, Issue 3, 2011, Pages 259-265

  Ramos, Oliberto Sánchez ^a   Pose, Alain González ^b   Gómez Puerta, Silvia ^a   Gomez, Julia Noda ^c   Redondo, Armando Vega ^c   Benites, Julio César Águila ^b   Amarán, Lester Suárez ^d   Parra, Natalie C ^a   Toledo Alonso, Jorge R ^a  

^a UNIVERSITY OF CONCEPCIÓN   (Chile)

^b CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

^c National Center for Animal and Plant Health CENSA   (Cuba)

^d UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Adenoviral vector; CD154; H5N1; Immune response; Influenza vaccine; Molecular adjuvant

Indexed keywords

ADENOVIRUS VECTOR; CD40 ANTIGEN; CD40 LIGAND; GAMMA INTERFERON; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY TITER; ANTIGEN ANTIBODY REACTION; ANTIGEN PRESENTATION; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; HEMAGGLUTINATION INHIBITION TEST; HUMORAL IMMUNITY; IMMUNOGENICITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; QUANTITATIVE ANALYSIS;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, VIRAL; CD40 LIGAND; CELL LINE; CHICKENS; GENE ORDER; GENETIC VECTORS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; MICE; RECOMBINANT FUSION PROTEINS; VIRAL VACCINES;

ADENOVIRIDAE; AVES; AVIAN INFLUENZA VIRUS; GALLUS GALLUS;

EID: 79955124746     PISSN: 01479571     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cimid.2010.12.001     Document Type: Article

References (33)

1. Ferreira T.B., Alves P.M., Aunins J.G., Carrondo M.J.T. Use of adenoviral vectors as veterinary vaccines. Gene Ther 2005, 12:S73-S83.
2. Maeda K., West K., Hayasaka D., Ennis F.A., Terajima M. Recombinant adenovirus vector vaccine induces stronger cytotoxic T-cell responses than recombinant vaccinia virus vector, plasmid DNA, or a combination of these. Viral Immunol 2005, 18:657-667.
3. Tatsis N., Ertl H.C.J. Adenoviruses as vaccine vectors. Mol Ther 2004, 10:616-629.
4. Hoelscher M.A., Garg S., Bangari D.S., Belser J.A., Lu X., Stephenson I., et al. Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet 2006, 367:475-481.
5. Toro H., Tang D.C., Suarez D.L., Zhang J., Shi Z. Protection of chickens against avian influenza with non-replicating adenovirus-vectored vaccine. Vaccine 2008, 26:2640-2646.
6. Toro H., Tang D.C. Protection of chickens against avian influenza with nonreplicating adenovirus-vectored vaccine. Poult Sci 2009, 88:867-871.
7. Grewal I.S., Flavell R.A. CD40 CD154 in cell-mediated immunity. Annu Rev Immunol 1998, 16:111-135.
8. van Kooten C., Banchereau J. CD40-CD40 ligand: a multifunctional receptor-ligand pair. Adv Immunol 1996, 61:1-77.
9. Banchereau J., Blanchard D., Briere F., Liu Y.J. Molecular control of B-cell immunopoiesis. Ann NY Acad Sci USA 1994, 725:22-33.
10. Foy T.M. gp39-CD40 interactions are essential for germinal center formation and the development of B cell memory. J Exp Med 1994, 180:157-163.
11. Burdin N. Inability to produce IL-6 is a functional feature of human germinal center B lymphocytes. J Immunol 1996, 156:4107-4113.
12. Gurunathan S., Irvine K.R., Wu C.Y., Cohen J.I., Thomas E., Prussin C., et al. CD40 ligand/trimer DNA enhances both humoral and cellular immune responses and induces protective immunity to infectious and tumor challenge. J Immunol 1998, 161:4563-4571.
13. Hilleman M.R. Realities and enigmas of human viral influenza: pathogenesis, epidemiology and control. Vaccine 2002, 20:3068-3087.
14. Tripp R.A., Jones L., Anderson L.J., Brown M.P. CD40 ligand (CD154) enhances the Th1 and antibody responses to respiratory syncytial virus in the BALB/c mouse. J Immunol 2001, 64:5913-5921.
15. Xiang R., Primus F.J., Ruehlmann J.M., Niethammer A.G., Silletti S., Lode H.N., et al. A dual-function DNA vaccine encoding carcinoembryonic antigen and CD40 ligand trimer induces T cell-mediated protective immunity against colon cancer in carcinoembryonic antigen-transgenic mice 1. J Immunol 2001, 167:4560-4565.
16. Gares S.L., Fischer K.P., Congly S.E., Lacoste S., Addison W.R., Tyrrell D.L., et al. Immunotargeting with CD154 (CD40 ligand) enhances DNA vaccine responses in ducks. Clin Vaccine Immunol 2006, 13:958-965.
17. Tregaskes C.A., Glansbeek H.L., Gill A.C., Hunt L.G., Burnside J., Young J.R. Conservation of biological properties of the CD40 ligand, CD154 in a non-mammalian vertebrate. Dev Comp Immunol 2005, 29:361-374.
18. Herrera A.M., Rodríguez E.G., Hernández T., Sández B., Duarte C.A. A family of compact plasmid vectors for DNA immunization in humans. Biochem Biophys Res Commun 2000, 279:548-551.
19. He T.C., Zhou S., da Costa L.T., Yu J., Kinzler K.W., Vogelstein B. A simplified system for generating recombinant adenovirus. Proc Natl Acad Sci USA 1998, 95:2509-2514.
20. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-685.
21. Kyhse-Andersen J. Electroblotting of multiple gels: a simple apparatus without buffer tank for rapid transfer of proteins from polyacrylamide to nitrocellulose. J Biochem Biophys Methods 1984, 10:203-209.
22. -ΔΔCT method. Methods 2001, 25:402-408.
23. Denton M.D., Reul R.M., Dharnidharka V.R., Fang J.C., Ganz P., Briscoe D.M. Central role for CD40/CD40 ligand (CD154) interactions in transplant rejection. Pediatr Transplant 1998, 2:6-15.
24. Phipps R.P., Koumas L., Leung E., Reddy S.Y., Blieden T., Kaufman J. The CD40-CD40 ligand system: a potential therapeutic target in atherosclerosis. Curr Opin Investig Drugs 2001, 2:773-777.
25. Sime P.J., O'Reilly K.M. Fibrosis of the lung and other tissues: new concepts in pathogenesis and treatment. Clin Immunol 2001, 99:308-319.
26. Layton S.L., Kapczynski D.R., Higgins S., Higgins J., Wolfenden A.D., Liljebjelke K.A., et al. Vaccination of chickens with recombinant Salmonella expressing M2e and CD154 epitopes increases protection and decreases viral shedding after low pathogenic avian influenza challenge. Poult Sci 2009, 88:2244-2252.
27. Graf D., Muller S., Korthauer U., van Kooten C., Weise C., Kroczek R.A. A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation. Eur J Immunol 1995, 25:1749-1754.
28. Pullen S.S., Labadia M.E., Ingraham R.H., McWhirter S.M., Everdeen D.S., Alber T., et al. High-affinity interactions of tumor necrosis factor receptor-associated factors (TRAFs) and CD40 require TRAF trimerization and CD40 multimerization. Biochemistry 1999, 38:10168-10177.
29. Li W. Synergistic antibody induction by antigen-CD40 ligand fusion protein as improved immunogen. Immunology 2005, 115:215-222.
30. Manoj S., Griebel P.J., Babiuk L.A., van Drunen Littel-van den Hurk S Targeting with bovine CD154 enhances humoral immune responses induced by a DNA vaccine in sheep. J Immunol 2003, 170:989-996.
31. Gao W., Soloff A.C., Lu X., Montecalvo A., Nguyen D.C., Matsuoka Y., et al. Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization. J Virol 2006, 80:1959-1964.
32. Van Kampen K.R., Shi Z., Gao P., Zhang J., Foster K.W., Chen D.T., et al. Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine 2005, 23:1029-1036.
33. Wesley R.D., Tang M., Lager K.M. Protection of weaned pigs by vaccination with human adenovirus 5 recombinant viruses expressing the hemagglutinin and the nucleoprotein of H3N2 swine influenza virus. Vaccine 2004, 22:3427-3434.